Abstracts tagged "Intravenous immunoglobulin (IVIG)"

Abstract Number: 113 • 2020 Pediatric Rheumatology Symposium
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
Alexis Wilsey¹, Heather Van Mater ² and Laura Cannon ², ¹Durham, ²Duke University, Durham
Background/Purpose: Rituximab is standard therapy in treating autoimmune brain disease (ABD) including refractory autoimmune encephalitis (AE) and Neuromyelitis Optica Spectrum Disease (NMOSD). Recommendations for continuing…
Abstract Number: 1558 • 2018 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin Efficacy for Primary Sjögren’s Syndrome Associated Small Fiber Neuropathy
Antoine Gaillet¹, Karine Champion¹, Jean-Pascal Lefaucheur², Herve Trout³, Jean-François Bergmann¹ and Damien Sène⁴, ¹Internal Medicine Department, Lariboisière Hospital, Paris, France, ²Clinical Neurophysiology Unit,, Henri-Mondor Hospital, Créteil, France, ³Pharmacy Department, Lariboisière Hospital, Paris, France, ⁴Lariboisière Hospital, Paris Diderot University, Paris, France
Background/Purpose: To analyze the efficacy and tolerance of intravenous immunoglobulin (IVIG) therapy in 11 patients with primary Sjögren's syndrome (pSS)-associated small-fiber neuropathy (SFN).Methods: Retrospective, single-center…
Abstract Number: 2888 • 2017 ACR/ARHP Annual Meeting
Corticosteroid-Sparing Benefit of Intravenous Immunoglobulins in Systemic Sclerosis-Associated Inflammatory Myopathy: A Retrospective Study of 54 Patients
Benjamin Chaigne¹, Simao Rodeia², Nouria Benmostefa^2,3,4, Alice Bérezné⁵, Pascal Cohen⁶, Alexis Regent⁷, Benjamin Terrier⁶, Nathalie Costedoat-Chalumeau⁸, Loïc Guillevin⁹, Claire Le Jeunne⁶ and Luc Mouthon¹⁰, ¹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares d’Ile de France, hôpital Cochin, DHU Authors, Assistance Publique-Hôpitaux de Paris, Paris, France, ²Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares d’Ile de France, DHU Authors, hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Service de Médecine Interne CHU de Sétif, Algérie, Sétif, Algeria, ⁴Faculté de Médecine, Université de Sétif 1, Sétif, Algeria, ⁵Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁶Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁸Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁹Internal medicine, Cochin University Hospital, paris, France, ¹⁰Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Little is known about systemic sclerosis (SSc)-associated myopathy (SScAM) treatment. Intravenous immunoglobulin (IVIg) are used off-label in SScAM. Herein we aimed to evaluate the…
Abstract Number: 2316 • 2016 ACR/ARHP Annual Meeting
Successful Treatment of Statin-Induced Autoimmune Myopathy without Corticosteroids
Geneviève Oligny Longpré¹, Yves Troyanov¹, Marvin J. Fritzler², José Ferreira¹, Ira N. Targoff³, Hélène Couture⁴, Océane Landon-Cardinal¹, Eric Rich¹, Josiane Bourré-Tessier⁵, Anne-Marie Mansour¹, Julie Drouin¹, Sandra Chartrand¹, Edith Villeneuve¹, Jean-Richard Goulet¹, Benjamin Ellezam⁶, Ana Maria Tsanaclis¹, Vincent Morin¹, Marie-Pierre Fournier-Gosselin¹ and Jean-Luc Senécal¹, ¹Université de Montréal, Montréal, QC, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³University of Oklahoma, Oklahoma City, OK, ⁴Université Laval, Québec, QC, Canada, ⁵Université de Montréal, Montreal, QC, Canada, ⁶Centre hospitalier universitaire Ste-Justine, Montréal, QC, Canada
Methods: Our study included all patients from the Université de Montréal AIM cohort (comprising four academic hospitals) with a documented anti-3-hydroxy-3-methylglutaryl-CoA reductase (anti-HMGCR) autoantibody. We selected…
Abstract Number: 948 • 2015 ACR/ARHP Annual Meeting
Autoimmune Myopathies: Effects of Intravenous Immunoglobulin Therapy on Muscle Strength and Predictors of Response
Arash Lahoutiharahdashti¹, Iago Pinal-Fernandez², Jemima Albayda¹, Julie J. Paik³, Sonye K. Danoff⁴, Andrew Mammen⁵ and Lisa Christopher-Stine⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Autoimmune Systemic Diseases Unit, Vall D’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There is a variable response rate to Intravenous immunoglobulin (IVIG) in patients with autoimmune myopathies. The aim of this study was to determine whether…
Abstract Number: 2565 • 2015 ACR/ARHP Annual Meeting
ACPA Specific IVIG Attenuate Collagen Induced Arthritis in Mice
Shaye Kivity¹, Nina Svetliscky¹, Qusim Odeh¹, Smadar Gertel¹, Howard Amital¹, Omer Gendelman¹, Iris Barshack², Alexander Volkov², Eran Bar-Meir³, Miri Blank¹ and Yehuda Shoenfeld⁴, ¹Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ²Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ³Plastic surgeon Poria Medical Center affiliated to Faculty of medicine in the Galilee Bar-Ilan university, Poria, Israel, ⁴Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel
Background/Purpose: Administration of intravenous-immunoglobulin (IVIg) is a recognized safe and efficient immunomodulatore therapy for many autoimmune diseases. Anti-idiotypic antibody binding to pathogenic autoantibodies was proposed…
Abstract Number: 2199 • 2014 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin Therapy for Secondary Hemophagocytic Lymphohistiocytosis : A Retrospective Study of 46 Patients
Bertrand Dunogué¹, Magdalena Gerin², Claire Larroche³, Catherine Montagnier-Petrissans⁴, Loïc Guillevin⁵ and Luc Mouthon⁵, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²Internal Medicine, Hôpital Jean Verdier, Bondy, France, ³Internal Medicine, Hôpital Avicenne, Bobigny, France, ⁴Groupe d'Expert AP-HP, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Intravenous Immunoglobulins (IVIg) have been reported as giving good results in infectious, but also auto-immune related forms of hemophagocytic lymphohistiocytosis (HLH), but only in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].